Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  04:03 2022-09-30 pm EDT
43.76 USD   -0.91%
09/30Indonesia to produce China's new COVID vaccine
RE
09/30A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia
RE
09/29Around 3.2 million Americans received updated COVID boosters last week -CDC
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pfizer CEO tests positive for COVID-19, has mild symptoms

08/15/2022 | 12:16pm EDT

The top executive at Pfizer, a leading producer of COVID-19 vaccines, has tested positive for the virus and says he is experiencing very mild symptoms.

Chairman and CEO Albert Bourla said Monday that he started taking Pfizer’s Paxlovid pill treatment and is isolating while he recovers.

Bourla has received four shots of Comirnaty, the COVID-19 vaccine developed by the New York drugmaker along with BioNTech. He said in a brief statement issued by the company that he is confident of a quick recovery.

More than 128 million people in the United States have become fully vaccinated with Pfizer’s two-shot vaccine since it entered the market more than a year ago and almost 61 million have received an initial booster shot, according to the Centers for Disease Control and Prevention.

Scientists say the vaccine still offers solid protection against hospitalization and serious illness. But the evolving virus has made it tougher for vaccines to prevent all forms of illness from developing.

Pfizer and another vaccine maker, Moderna, are updating their shots to provide protection against newer versions of the virus for a fall booster campaign.

Paxlovid also has shown in research to be extremely effective at warding off serious illness if it is administered shortly after symptoms start.

Comirnaty and Paxlovid are the top-selling COVID-19 vaccine and treatment on the market. Combined, they brought in nearly $17 billion in sales for Pfizer during the recently completed second quarter.

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about PFIZER, INC.
09/30Indonesia to produce China's new COVID vaccine
RE
09/30A Chinese mRNA COVID vaccine is approved for the first time - in Indonesia
RE
09/29Around 3.2 million Americans received updated COVID boosters last week -CDC
RE
09/29Biohaven's ALS drug fails to meet study goals
RE
09/28Indonesia approves first home-grown COVID vaccine for emergency use - media
RE
09/28Merck agrees to allow Sinopharm to sell molnupiravir COVID drug in China
RE
09/28Pfizer, BioNTech Seeks European Nod for COVID Vaccine Booster for Children 5 to 11
MT
09/28Pfizer, BioNTech File European Medicines Agency Application for Omicron Booster Dose fo..
MT
09/28Indonesia approves first home-grown COVID vaccine for emergency use - media
RE
09/27Japan's Shionogi says COVID pill reaches endpoint in Phase III trial
RE
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 102 B - -
Net income 2022 32 739 M - -
Net cash 2022 10 262 M - -
P/E ratio 2022 7,73x
Yield 2022 3,70%
Capitalization 246 B 246 B -
EV / Sales 2022 2,32x
EV / Sales 2023 2,88x
Nbr of Employees 79 000
Free-Float 59,0%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 43,76 $
Average target price 55,75 $
Spread / Average Target 27,4%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-25.89%245 597
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY17.06%307 239
ROCHE HOLDING AG-14.68%271 055
ABBVIE INC.-0.88%237 296
NOVO NORDISK A/S3.59%227 057